is supported by the National Institute of General Medical Sciences (NIGMS) grant P20GM109025, National Institute on Aging (NIA) grants R35AG71476 and R25AG083721-01, National Institute of Neurological Disorders and Stroke (NINDS) grant RO1NS139383, the Alzheimers Drug Discovery Foundation (ADDF), Ted and Maria Quirk Endowment, and Joy Chambers-Grundy Endowment
10.3389/fphar.2021.632295 Summary Keywords gastric pentadecapeptide BPC 157, primary abdominal compartment syndrome, rats, brain edema, lung edema Citation Tepes M, Gojkovic S, Krezic I, Zizek H, Vranes H, Madzar Z, Santak G, Batelja L, Milavic M, Sikiric S, Kocman I, Simonji K, Samara M, Knezevic M, Barisic I, Lovric E, Strbe S, Kokot A, Sjekavica I, Kolak T, Skrtic A, Seiwerth S, Boban Blagaic A and Sikiric P (2021) Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
Additionally, Nrf2 knockdown showed an inhibitory effect on the reduction of MDA, iron content and ROS compared with the DAPA treatment group (Fig
your bodys energy factories), glutathione helps improve energy production at the cellular level